85. Idiopathic interstitial pneumonia Clinical trials / Disease details

Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

diseases per page:

Showing 1 to 10 of 598 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03800017 (ClinicalTrials.gov)	September 1, 2022	21/11/2018	Skeletal Muscle Function in Interstitial Lung Disease	Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interst ...	Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis;Scleroderma;Non ...	Biological: Hyperoxia	University of British Columbia	NULL	Not yet recruiting	40 Years	80 Years	All	40	N/A	NULL
2	NCT05255991 (ClinicalTrials.gov)	September 2022	15/2/2022	Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmo ...	A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Saf ...	Idiopathic Pulmonary Fibrosis;Interstitial Lung Disease	Drug: Placebo;Drug: Inhaled Treprostinil;Device: Treprostinil Ultrasonic Nebulizer	United Therapeutics	NULL	Not yet recruiting	40 Years	N/A	All	396	Phase 3	NULL
3	NCT04905693 (ClinicalTrials.gov)	June 2022	20/5/2021	Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis	An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis ...	Idiopathic Pulmonary Fibrosis;Interstitial Lung Disease	Drug: Inhaled Treprostinil;Device: Treprostinil Ultrasonic Nebulizer	United Therapeutics	NULL	Not yet recruiting	40 Years	N/A	All	792	Phase 3	NULL
4	NCT05195918 (ClinicalTrials.gov)	April 1, 2022	2/12/2021	Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients	Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients Wi ...	Idiopathic Pulmonary Fibrosis	Combination Product: EGCG + Nintedanib;Combination Product: EGCG + Pirfenidone;Combination Product: ...	Hal Chapman	University of Michigan;Cornell University;Massachusetts General Hospital;Temple University	Not yet recruiting	40 Years	85 Years	All	50	Phase 1	United States
5	EUCTR2021-001253-32-GR (EUCTR)	04/03/2022	27/12/2021	A Study to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pul ...	A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: HZN-825 INN or Proposed INN: HZN-825 Other descriptive name: SAR100842	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 2	United States;Taiwan;Greece;Spain;Turkey;Chile;United Kingdom;Italy;France;Mexico;Canada;Argentina;B ...
6	NCT05241275 (ClinicalTrials.gov)	March 1, 2022	3/2/2022	Xenon MRI and Progressive ILD	XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD	Idiopathic Pulmonary Fibrosis;Progressive Pulmonary Fibrosis	Drug: Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment	Duke University	Boehringer Ingelheim	Not yet recruiting	18 Years	N/A	All	75	Phase 2	NULL
7	NCT05154240 (ClinicalTrials.gov)	February 21, 2022	17/11/2021	A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects ...	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Oral Single and Multiple Ascending Doses, P ...	Idiopathic Pulmonary Fibrosis	Drug: INS018_055;Drug: Placebo	InSilico Medicine Hong Kong Limited	NULL	Not yet recruiting	18 Years	55 Years	All	80	Phase 1	New Zealand
8	EUCTR2021-001253-32-ES (EUCTR)	16/02/2022	07/12/2021	A Study to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pul ...	A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate ...	Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idio ...	Product Code: HZN-825 INN or Proposed INN: HZN-825 Other descriptive name: SAR100842	Horizon Therapeutics Ireland DAC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 2	United States;Taiwan;Greece;Spain;Turkey;Chile;United Kingdom;Italy;France;Mexico;Canada;Argentina;P ...
9	NCT05016817 (ClinicalTrials.gov)	February 2022	17/8/2021	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusio ...	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusio ...	Idiopathic Pulmonary Fibrosis	Biological: AlloRx	The Foundation for Orthopaedics and Regenerative Medicine	NULL	Recruiting	N/A	N/A	All	20	Phase 1	Antigua and Barbuda
10	NCT05130970 (ClinicalTrials.gov)	January 27, 2022	12/11/2021	CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis	A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, a ...	Idiopathic Pulmonary Fibrosis	Drug: CSL312;Drug: Placebo	CSL Behring	NULL	Recruiting	40 Years	N/A	All	80	Phase 2	United States;Canada

First Previous1 2 3 4 5…60Next Last